There are two opposing attitudes
to paths that have not been taken
Fear that there are no known paths
and excitement that new paths can be pioneered
At GC Biopharma, the fundamental question that guides our endeavors is how quickly we can develop the new drugs patients have long awaited. We have been a trailblazer in bio-pharmaceuticals, developing groundbreaking plasma derivatives, vaccines, and recombinants one after another. GC Biopharma’s dedication to innovation has brought the company shoulder to shoulder with other world-class providers of life science solutions.
Drugs that are difficult to make
but that must be made
Paths that are best avoided
but that must be pioneered
GC Biopharma has spearheaded the development of drugs that are extremely difficult to make, but that must be made to free patients from the despair of disease. At GC Biopharma, we have dared, with a pioneering spirit, to take on the challenge of developing specialized drugs avoided by other pharmaceutical companies. Belief in the value of a society where everyone has a chance at happiness, free from the pain of disease, leads us along this path.
Over the last 50 years
To the next 50 years
For the 100 years of humanity
The way of a hundred-year enterprise
Our commitment to preparing for the next 50 years, High 5, GC, is a mid- to long-term 2030 plan that represents five new global medicines, 5 trillion won in sales, and 50 trillion won in corporate value. It's a strategy to become a great company that will lead the global health industry. The GC, a company which has written a new history of Korean pharmaceutical industry, is now dreaming of a vision of the next 50 years beyond the last 50 years with its mission and desire for human health.
The great enterprise spirit of the GC Biopharma
As we have walked in the last half century, we will contribute to the treatment of diseases and the health of the people through the development of difficult but essential medicines for patients. We will also implement the GC's vision to maximize the effectiveness and value of existing products, and to strengthen the new medicine pipeline for various diseases to provide a healthy life for mankind.
- Announcement U.S. FDA Accepts Biologics License Application for GC Biopharma's GC5107B (Immune Globulin Intravenous (Human), 10% Liquid) 2023.08.16
- Announcement GC Biopharma's "GC FLU" obtains vaccine approval in Egypt: First-ever approval of the company's quadrivalent flu vaccine on the African continent 2023.08.16
- Announcement GC Biopharma receives a business license for the construction of a plasma fractionation plant and technology transfer in Indonesia 2023.08.16
-
- Pharmaceutical
- GC MS
- GC Wellbeing
- GC Medis
-
- Overseas
- GC China Pharm
- Curevo
- GC Pharma do Brasil
-
- Foundation
- MOGAM Institue
- GC Labs
- GC i-Med
-
- Others
- GC Invacfarm